New clinical trial : personalized medicine in diabetes using a nanotechnology platform


Rambam Health Care Campus in Israel will launch in collaboration with Technion/Israel Institute of Technology a phase I clinical trial about “personalized medicine in diabetes using a nanotechnology platform”, registered in the Clinicaltrials.gov database under reference NCT01268813. In this trial, breath samples will be collected in inert respiratory bag from diabetic and healthy volunteers, and analyzed using a chamber containing nano-chemical sensors. These samples together with blood samples will additionally be characterized using Gas Chromatography-Mass Spectroscopy (GC-MS). The study is not yet open for participant recruitment.

New clinical trial – Abraxane and carboplatin as first-line treatment for triple negative metastatic breast cancer


Duke University and Abraxis Bioscience recently started a phase II clinical trial involving Abraxane (nanoparticle albumin-bound paclitaxel), now registered in the Clinicaltrials.gov database under reference NCT01207102. The primary objective of the trial is to statistically test whether Abraxane and carboplatin can improve progression-free survival as first-line treatment for “triple negative” (no expression for estrogen, progesterone, or HER2 receptors) metastatic breast cancer. The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

Nanoparticles in clinical trial trends : comments & focus on Abraxane ]]]

New clinical trial – capsaicin nanoparticles in patients with painful diabetic neuropathy


Mahidol University and the Thailand Research Fund recently started a phase II/III clinical trial involving a capsaicin nanoparticle preparation, now registered in the Clinicaltrials.gov database under reference NCT01125215. According to this page, the aim is to “determine efficacy and safety of 0.75% topical capsaicin nanoparticle preparation versus placebo in patient with painful diabetic neuropathy“. The study is currently recruiting participants.

Gates Foundation funds innovative global health projects including sweat-triggered vaccine delivery using nanoparticles


The Bill & Melinda Gates Foundation announced a few days ago 78 grants of US$100,000 each for new innovative global health projects. Among those aiming at more effective vaccines, one involves nanoparticles : “Sweat-triggered vaccine delivery: Carlos Alberto Guzman of the Helmholtz Centre for Infection Research in Germany with Claus-Michael Lehr and Steffi Hansen of the Helmholtz-Institute for Pharmaceutical Research will develop nanoparticles that penetrate the skin through hair follicles and burst upon contact with human sweat to release vaccines.” (press release)

[[[ Additional link suggested by Nanocolors :

# Nano & vaccines in patents since 2000 ]]]

New phase I clinical trial involving a polymeric nanoparticle formulation of docetaxel


Korean company Samyang started in April 2010 a phase I clinical trial involving a polymeric nanoparticle formulation of docetaxel, now registered in the Clinicaltrials.gov database under reference NCT01103791. According to this page, the aim is to “determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies“.

New clinical trial involving a paclitaxel nanoparticle formulation


With the collaboration of Abbott, a Wake Forest University scientist is conducting a clinical trial to study the best dose and best way to give paricalcitol and to see how well it works when given together with chemotherapy in treating patients with metastatic breast cancer. It is now registered in the ClinicalTrials.gov database under reference NCT01055288. According to this page : “Beginning on day 1, patients receive oral paricalcitol. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation, docetaxel, or paclitaxel once a week or ixabepilone once every 3 weeks. Treatment continues for at least 12 weeks in the absence of disease progression or unacceptable toxicity

Clinical Applications of Nanotechnologies in the Field of Cancer


The “Clinical applications of nanotechnologies in cancer” conference will take place in Montpellier (France) on January 28 and 29, 2010. According to the program, the sessions will focus on the following topics :

SESSION 1: Presentation of nano research activities: IBEC/Biopol L´H-Barcelona, Cancéropôle Grand Sud-Ouest and Cancéropôle Lyon Auvergne Rhône-Alpes

SESSION 2: Transfer of nanotechnology to clinical applications related to cancer 
 
SESSION 3: Ethics and regulatory issues related to nanotechnologies in the field of cancer

SESSION 4: Proof of concept of clinical applications in oncology  

[[[ Additional links suggested by Nanocolors :

# Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

# A nanotech sensor to distinguish between the breath of lung cancer patients and healthy controls

 # Gold nanoparticles for cancer detection animation

# Fighting cancer with magnetic nanoparticles – animation ]]]